Health News Releases

  • Today September 10
Urethral stricture starts with narrowing of a short segment of urethral lumen. At early stages, it i
May 11, 16:50
Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 2026
A path breaking scientific discovery, unraveling successful wound healing mechanism in urethral stricture with BEES-HAUS (https://www.ncrm.org/myth/beeshaus/) cell therapy has been reported by Indo-Ja
May 10, 15:25
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of
WHOOP Expands Health Platform with On-Demand Clinician Access and New AI Features
May 10, 13:30
WHOOP Expands Health Platform with On-Demand Clinician Access and New AI Features
WHOOP (https://www.whoop.com/kr/en/?utm_source=PR&utm_medium=PR&utm_campaign=SR_A), the human performance company, today announced a new suite of health and AI-driven enhancements and feature updates
HE Mansoor Al Mansoori (Left) and Tom Hale (Right)
May 08, 16:50
Department of Health - Abu Dhabi and ŌURA Partner to Advance Preventive Health in Abu Dhabi
Department of Health—Abu Dhabi (https://www.doh.gov.ae/en/) (DoH) and ŌURA (https://ouraring.com/ko?srsltid=AfmBOormyEZs4LuQCQfSGbmxbAuvAy4qBM3q7akrgnjiPIzDNqS2nZh9), maker of the world’s leading smar
May 06, 16:25
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), m
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Mo
May 04, 16:00
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Wid
May 03, 17:20
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership
CorFlow Therapeutics AG (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.corflow.com&esheet=54526078&newsitemid=20260430413675&lan=en-US&anchor=CorFlow+Therapeutics+AG&index=1&md5
May 03, 16:00
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis
MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH
May 03, 11:40
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation
SS&C Technologies Holdings, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ssctech.com%2F%3Futm_campaign%3DSSC2026-Enterprise-Press-Release-0426%26utm_medium%3Dpressreleas
May 03, 11:00
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54524717&newsitemid=20260429582815&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
May 03, 10:40
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal
David Weinreich, Global Head of R&D and Chief Medical Officer
May 03, 10:20
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481 (https://cts.businesswire.com/ct/CT?id=smartlink&url=h
Masimo RD SET® Neo Pulse Oximetry Sensor
April 30, 16:10
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study
Masimo (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54524005&newsitemid=20260428136753&lan=en-US&anchor=Masimo&index=1&md5=9061676d45e4b2fdccbe6887499605e3)
Dr. Vivek Mundada with Medcare multidisciplinary medical team (Photo: AETOSWire)
April 30, 09:40
Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US
Medcare Royal Speciality Hospital (MRSH) in Dubai has become the world’s first hospital outside the USA, to offer a newly licensed intrathecal gene therapy - Itvisma, to adult patients with Spinal Mus
Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equi
April 30, 08:55
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), today announced that the compan
Credits to Roquette
April 29, 17:15
Roquette Showcases Its Expanded Consumer Healthcare Capabilities at Vitafoods Europe 2026
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will present its expanded portfolio at Vitafoods Europe 2026 which is taking place from May 5 to May 7 in
April 29, 13:13
Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific
Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as “ATLATL”), global innovation platform for life science research and development, today announced that the companies h
PCI Pharma Services announced a series of major infrastructure investments that substantially deepen
April 28, 16:00
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities
PCI Pharma Services (“PCI”) - a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies - announced a ser
April 28, 15:40
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adu
Sun Pharma signs Definitive Agreement to Acquire Organon
April 28, 15:30
Sun Pharma signs Definitive Agreement to Acquire Organon
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (N
Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt
April 27, 15:20
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health
Today, the Higher Regional Court of Frankfurt upheld the February 2025[1] partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia
First-in-human contrast enhanced MRI images with GE HealthCare’s mangaciclanol
April 24, 13:51
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents
GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI)
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
April 24, 11:10
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Agenus (https://www.agenusbio.com/) Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma (https://bappharma.com/), a global medicines access and clinical trial supply company, t
April 23, 16:33
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. · Strong start to the year delivering net sales of 1,47
April 23, 15:51
Galderma Shareholders Approve All Annual General Meeting Proposals
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), h
25 per page50 per page75 per page100 per page